[Combined effects of sizofiran and rG-CSF on myelosuppression in cancer chemotherapy].
A combination of the antitumor polysaccharide Sizofiran and rG-CSF was investigated for its effects on peripheral blood counts in ovarian cancer patients undergoing chemotherapy. We performed the analysis by using variations in peripheral blood counts and the duration of treatment as variables. In the analysis, effects on decreases in both neutrophils and platelets and their recoveries could be assessed. As a result, the decrease in neutrophils was inhibited and its recovery was promoted, suggesting that the combined use of the drugs may be useful for myelosuppression by chemotherapy for ovarian cancer.
Hoshino
T
T
Department of Obstetrics and Gynecology, Tokyo Medical College, Japan.
Suzuki
Y
Y
Takeichi
M
M
Adachi
T
T
Takayama
M
M
D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001854:Bone Marrow Cells; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D018282:Cystadenocarcinoma, Mucinous / Q000628:therapy; D018284:Cystadenocarcinoma, Serous / Q000628:therapy; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D006801:Humans; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced / Q000517:prevention & control; D010051:Ovarian Neoplasms / Q000628:therapy*; D011994:Recombinant Proteins / Q000008:administration & dosage; D012566:Sizofiran / Q000008:administration & dosage*; D013921:Thrombocytopenia / Q000139:chemically induced / Q000517:prevention & control
D000972:Antineoplastic Agents, Phytogenic; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D012566:Sizofiran; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin